Search research articles
Contact Us
Filters
Showing results (101-110 of 216) with videos related to
Page
of 22
Sort By:
Arthritis Care & Research
|
March 27, 2018
Reply
Nicolai Leuchten, George Bertsias, Josef Smolen, et al.
The British Journal of Dermatology
|
March 23, 2022
Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib
Kristina Fischer, Martin Aringer, Julian Steininger, et al.
Acta Dermato-Venereologica
|
December 16, 2011
TNF-alpha blockade with infliximab in a patient with lupus erythematosus profundus
Claudia Günther, Martin Aringer, Marlene Lochno, et al.
Arthritis and Rheumatism
|
January 1, 2009
Identification of relevant concepts of functioning in daily life in people with systemic lupus erythematosus: A patient Delphi exercise
Bettina Bauernfeind, Martin Aringer, Birgit Prodinger, et al.
Zeitschrift Fur Rheumatologie
|
January 27, 2026
[Why C-reactive protein is (usually) not high in SLE]
Erik Klapproth, Martyna Hempel, Nicolai Leuchten, et al.
Clinical Rheumatology
|
May 20, 2023
Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial
Eric L Matteson, Martin Aringer, Gerd R Burmester, et al.
Annals of the Rheumatic Diseases
|
January 20, 2007
The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis
László Czirják, Zoltán Nagy, Martin Aringer, et al.
Journal of Neurology
|
October 27, 2025
Methotrexate therapy as a promising long-term treatment approach for immune-mediated adverse reactions of tofersen in SOD1-ALS: a case report
Maximilian Vidovic, Hanna Sophie Lapp, Isabelle Dittes, et al.
Arthritis and Rheumatism
|
December 30, 2006
Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus
Martin Aringer, Günter Steiner, Winfried B Graninger, et al.
RMD Open
|
December 24, 2024
Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases
Martin Aringer, Oliver Distler, Anna-Maria Hoffmann-Vold, et al.
Page
of 22
Search research articles
Search
Showing results (101-110 of 216) with videos related to
Sort By:
Page
of 22
Arthritis Care & Research
|
March 27, 2018
Reply
Nicolai Leuchten, George Bertsias, Josef Smolen, et al.
The British Journal of Dermatology
|
March 23, 2022
Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib
Kristina Fischer, Martin Aringer, Julian Steininger, et al.
Acta Dermato-Venereologica
|
December 16, 2011
TNF-alpha blockade with infliximab in a patient with lupus erythematosus profundus
Claudia Günther, Martin Aringer, Marlene Lochno, et al.
Arthritis and Rheumatism
|
January 1, 2009
Identification of relevant concepts of functioning in daily life in people with systemic lupus erythematosus: A patient Delphi exercise
Bettina Bauernfeind, Martin Aringer, Birgit Prodinger, et al.
Zeitschrift Fur Rheumatologie
|
January 27, 2026
[Why C-reactive protein is (usually) not high in SLE]
Erik Klapproth, Martyna Hempel, Nicolai Leuchten, et al.
Clinical Rheumatology
|
May 20, 2023
Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial
Eric L Matteson, Martin Aringer, Gerd R Burmester, et al.
Annals of the Rheumatic Diseases
|
January 20, 2007
The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis
László Czirják, Zoltán Nagy, Martin Aringer, et al.
Journal of Neurology
|
October 27, 2025
Methotrexate therapy as a promising long-term treatment approach for immune-mediated adverse reactions of tofersen in SOD1-ALS: a case report
Maximilian Vidovic, Hanna Sophie Lapp, Isabelle Dittes, et al.
Arthritis and Rheumatism
|
December 30, 2006
Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus
Martin Aringer, Günter Steiner, Winfried B Graninger, et al.
RMD Open
|
December 24, 2024
Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases
Martin Aringer, Oliver Distler, Anna-Maria Hoffmann-Vold, et al.
Page
of 22